Objectives To assess cost-effectiveness of direct oral anticoagulants (DOACs) compared
with vitamin K antagonists (VKAs) for stroke prevention in atrial fibrillation (AF) by pooling …

Background: Big data and real-world data (RWD) have been increasingly used to measure
the effectiveness and costs in cost-effectiveness analysis (CEA). However, the …

Randomized controlled trials (RCTs) are preferred by payers for health technology
assessments and coverage decisions. However, the inclusion of a highly selective patient …

Background Atrial fibrillation (AF) is a severe epidemiological and public health concern
among the elderly population worldwide, with substantial economic and social burdens …

Abstract Background and Objective The decision to initiate anticoagulation in older adults
with atrial fibrillation is complicated by the benefit of ischemic stroke prevention vs the risk of …

Atrial fibrillation has a high disease burden—both in prevalence and associated
consequences. Despite anticoagulation being an effective treatment in atrial fibrillation …

Objective The objective was to assess the real-world cost-effectiveness of rivaroxaban,
versus vitamin K antagonists (VKAs), for stroke prevention in patients with atrial fibrillation …

The relevant cost-effectiveness study reports economic terms in the currency units of each
country at a certain time unit, so that currency conversion is needed for the standardization …

A cerebrovascular accident is a pathological entity with the vascular impairment of sudden
onset, which leads to the lowering of the level of consciousness, differentiating it into …

ABSTRACT BACKGROUND: Dabigatran 150 mg BID (D150) and rivaroxaban 20 mg (R20)
are indicated for the prevention of thromboembolic events in patients with Non-Valvular …